APLS
Apellis Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.25B
P/E Ratio
38.35
EPS
$1.07
Beta
-0.25
52W High
$41.14
52W Low
$3.48
50-Day MA
$32.78
200-Day MA
$25.97
Dividend Yield
—
Profit Margin
12.10%
Forward P/E
46.30
PEG Ratio
—
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.11B |
| Gross Profit (TTM) | $710.47M |
| EBITDA | $166.63M |
| Operating Margin | 9.87% |
| Return on Equity | 46.00% |
| Return on Assets | 10.90% |
| Revenue/Share (TTM) | $8.72 |
| Book Value | $3.24 |
| Price-to-Book | 12.66 |
| Price-to-Sales (TTM) | 4.75 |
| EV/Revenue | 4.816 |
| EV/EBITDA | 29.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 60.90% |
| Shares Outstanding | $128.02M |
| Float | $83.22M |
| % Insiders | 11.37% |
| % Institutions | 110.43% |
Analyst Ratings
Consensus ($40.92 target)
1
Buy19
HoldMore HEALTHCARE Stocks
Data last updated: 5/19/2026